Evidence map›Paper›PMID 19788390›Full record

ArticleHuman gene therapy2010

Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.

Giridhara R Jayandharan, Li Zhong, Brandon K Sack, Angela E Rivers, Mengxin Li, Baozheng Li, Roland W Herzog, Arun Srivastava

Abstract read
In one paragraph

Article in Human gene therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Engineering of Exosomes to Target Cancer Metastasis.Cellular and molecular bioengineering · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Emerging Issues in AAV-MediatedMolecular therapy. Methods & clinical development · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giridhara R JayandharanDivision of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL 32611-3633, USA.
Li Zhong
Brandon K Sack
Angela E Rivers
Mengxin Li
Baozheng Li
Roland W Herzog
Arun Srivastava

Funding

Vector CoreP01HL078810 · NHLBI · WISTAR INSTITUTE · PI ERTL, HILDEGUND C. J. · 2005 to 2014
$16.7M
Strategies for Sustained Effect of AAV-mediated Correction of Pompe DiseaseP01DK058327 · NIDDK · UNIVERSITY OF FLORIDA · PI CAMPBELL-THOMPSON, MARTHA · 2000 to 2009
$11.0M
Immunology of Factor IX Gene Transfer to LiverR01AI051390 · NIAID · UNIVERSITY OF FLORIDA · PI HERZOG, ROLAND W. · 2002 to 2022
$6.7M
Human Parvovirus B19 Vectors: Mechanism of TransductionR01HL076901 · NHLBI · UNIVERSITY OF FLORIDA · PI SRIVASTAVA, ARUN · 2004 to 2008
$1.8M
Parvovirus Vectors for Human Gene TherapyR01EB002073 · NIBIB · UNIVERSITY OF FLORIDA · PI SRIVASTAVA, ARUN · 2003 to 2004
$730k
NHLBI NIH HHS HL-076901NHLBI NIH HHS P01 HL-078810NHLBI NIH HHS R01 HL-065770NIAID NIH HHS R01 AI/HL-51390NIBIB NIH HHS R01 EB-002073NIDDK NIH HHS P01 DK-058327
6 · The paper itself

Abstract

Abstract Our studies have shown that coinjection of conventional single-stranded adeno-associated virus 2 (ssAAV2) vectors carrying the enhanced green fluorescent protein (EGFP) gene with self-complementary (sc) AAV2-T cell protein tyrosine phosphatase (TC-PTP) and scAAV2-protein phosphatase-5 (PP5) vectors resulted in an approximately 16-fold increase in EGFP expression in primary murine hepatocytes in vivo [Jayandharan, G.R., Zhong, L., Li, B., Kachniarz, B., and Srivastava, A. (2008). Gene Ther. 15, 1287-1293]. In the present studies, this strategy was further optimized to achieve transgene expression at reduced vector/helper virus doses. These included the use of scAAV helper viruses containing (1) hepatocyte-specific promoters, (2) tyrosine-mutant AAV2 capsids, and (3) additional AAV serotype vectors known to efficiently transduce hepatocytes. The hepatocyte-specific transthyretin (TTR) promoter was approximately 6- to 7-fold more efficient than the Rous sarcoma virus (RSV) promoter; tyrosine-mutant AAV2 capsids were approximately 6- to 11-fold more efficient than the wild-type AAV2 capsids; and the AAV8 serotype helper virus was approximately 16-fold more efficient than AAV2 serotype helper virus. With these modifications, the vector dose of the helper virus could be further reduced by approximately 50-fold. Last, coadministration of scAAV8-PP5 helper virus increased coagulation factor IX expression from an ssAAV2 vector by approximately 7- to 10-fold, thereby achieving therapeutic levels at lower vector doses. No adverse effect on hepatocytes was observed under any of these experimental conditions. The strategy presented here should be adaptable to any ssAAV transgene cassette and, specifically, liver-directed applications of ssAAV2 vectors containing larger genes that cannot be encapsidated in scAAV vectors.

Indexed as

Genetic VectorsTransduction, GeneticAnimalsDependovirusDNA, Single-StrandedFactor IXGene Transfer TechniquesGreen Fluorescent ProteinsHelper VirusesHepatocytesHumansImmunoenzyme TechniquesLiverMaleMiceMice, Inbred C57BLDNA, Single-Strandedenhanced green fluorescent proteinFactor IXGreen Fluorescent ProteinsNuclear ProteinsPhosphoprotein PhosphatasesPrealbuminprotein phosphatase 5Protein Tyrosine Phosphatase, Non-Receptor Type 2

Identifiers

PMID19788390
PMCPMC2865358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.